This article is more than 5 years old. Information may no longer be current.
Cleveland Clinic earns designation
Click Here to Manage Email Alerts
HHT Foundation International recently named Cleveland Clinic as the 15th HHT Center of Excellence in the United States.
Hereditary hemorrhagic telangiectasia (HHT), a genetic disorder that causes abnormalities of blood vessels, affects approximately one in 5,000 people. Individuals with HHT lack the capillaries that connect arteries to veins, leaving the gap very fragile and likely to rupture and result in bleeding.
Keith McCrae
The new HHT Center, which will fall under Cleveland Clinic’s Respiratory Institute, will collaborate with Keith McCrae, MD, a hematologist in the Taussig Cancer Institute who has treated patients with HHT for more than 20 years. McCrae intends to open a new clinical trial for patients with HHT in the next couple months.